Login to Your Account

Other News To Note

Wednesday, May 30, 2012
• Bionomics Ltd., of Adelaide, Australia, said it launched a Phase I/II trial of BNC105 in women with ovarian cancer. Up to 134 patients are expected to be enrolled in the study, which is designed to test the vascular-disrupting agent in combination with current standard therapies carboplatin and gemcitabine.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription